Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients- a Randomized, Placebo Controlled Phase II Trial "DEFENCE" (DEnosumab for the REductioN of the Smoldering Myeloma TransformatioN InCidence RatE)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Calcium carbonate (Primary) ; Colecalciferol (Primary) ; Denosumab (Primary)
Indications Smoldering multiple myeloma
Focus Therapeutic Use
Acronyms DEFENCE

Most Recent Events

11 Feb 2025 Status changed from active, no longer recruiting to completed.
21 Nov 2023 Planned End Date changed from 1 Jul 2024 to 14 Sep 2024.
30 Sep 2023 This trial has been completed in Austria (Date of the global end of the trial: 14-Sep-2023), according to the European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight